Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Reexamination Certificate
2005-05-24
2010-06-22
Woodward, Cherie M (Department: 1647)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
C512S002000
Reexamination Certificate
active
07741285
ABSTRACT:
The present invention relates generally to Apo2L/TRAIL purification involving crystallization.
REFERENCES:
patent: 5610279 (1997-03-01), Brockhaus et al.
patent: 5763223 (1998-06-01), Wiley et al.
patent: 5808029 (1998-09-01), Brockhaus et al.
patent: 6030945 (2000-02-01), Ashkenazi et al.
patent: 6284236 (2001-09-01), Wiley et al.
patent: 6541606 (2003-04-01), Margolin et al.
patent: 2007/0161564 (2007-07-01), Ashkenazi et al.
patent: 870827 (1998-10-01), None
patent: WO97/01633 (1997-01-01), None
patent: WO97/25428 (1997-07-01), None
patent: WO98/18921 (1998-07-01), None
patent: WO98/28426 (1998-07-01), None
patent: WO98/32856 (1998-07-01), None
patent: WO98/35986 (1998-08-01), None
patent: WO98/41629 (1998-09-01), None
patent: WO98/46643 (1998-10-01), None
patent: WO98/46751 (1998-10-01), None
patent: WO98/51793 (1998-11-01), None
patent: WO99/02653 (1999-01-01), None
patent: WO99/09165 (1999-02-01), None
patent: WO99/11791 (1999-03-01), None
patent: WO 99/36535 (1999-07-01), None
patent: WO 99/48527 (1999-09-01), None
patent: WO 00/75191 (2000-12-01), None
patent: WO01/00832 (2001-01-01), None
patent: WO 01/00832 (2001-01-01), None
patent: WO 0100832 (2001-01-01), None
patent: WO 02/09755 (2002-02-01), None
Cha et al., Acta Crystallogr D Biol Crystallogr. May 1999;55(Pt 5):1101-4.
Hymowitz et al., Biochemistry. Feb. 1, 2000;39(4):633-40.
Ray et al., Proteins. Oct. 1992;14(2):300-8, Abstract only.
Cha et al., Immunity. Aug. 1999; 11:253-261.
Baudier et al., FEBS Lett. Nov. 8, 1982;148(2):231-4, Abstract only.
Nelson et al., Eds. Lehninger Principles of Biochemistry. Third Ed. Worth Publishers. 2000, pp. 130-133.
SigmaAldrich catalog, Guanadine hydrocholoride.
Metric Conversions—277K = 4C.
McPherson (Eur J Biochem. 1990;189:1-23).
Armitage et al., “Molecular and Biological Characterization of a Murine Ligand for CD40”, Nature, 357(6373):80-82 (1992).
Ashkenazi et al., “Safety and Antitumor Activity of Recombinant Soluble Apo2 Ligand”Journal of Clinica;l Investigation 104(2):155-162 (1999).
Banner et al., “Crystal Structure of the Soluble Human 55 KD TNF Receptor-Human TNFβComplex: Implications for TNF Receptor Activation” Cell 73:431-445 (1993).
Bodmer et al., “Cysteine 230 is Essential for the Structure and Activity of the Cytotoxic Ligand Trail”, Journal of Biological Chemistry 275:20632-20637 (2000).
Brockaus et al., “Identification of Two Types of Tumor Necrosis Factor Receptors on Human Cell Lines by Monoclonal Antibodies”, Proc. Natl. Acad. Sci. USA 87:3127-3131 (1990).
Browning et al., “Lymphotoxin β, a Novel Member of the TNF family that Forms a Heteromeric Complex with Lymphotoxin on the Cell Surface” Cell 72:847-856 (1993).
Chicheportiche et al., “TWEAK, A New Secreted Ligand in the Tumor Necrosis Factor Family that Weakly Induces Apoptosis”, Journal of Biological Chemistry 272(51):32401-32410 (1997).
Chinnaiyan et al., “Combined Effect of Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand and Ionizing Radiation in Breast Cancer Therapy”, Proc. Natl. Acad. Sci. 97:1754-1759 (2000).
Darby et al., “Disulfide Bonds in Protein Folding and Stability”, Methods in Enzymology, B.A. Shirley, Totowa, NJ: Human Press Inc., Chpt. 10, vol. 40:219-252 (1995).
Dealtry et al., DNA Fragmentation and Cytotoxicity cause by Tumor Necrosis Factor is Enhanced by Interferon-γEuropean Journal of Immunology 17:689-693 (1987).
Delgi-Esposti et al., “Cloning and Characterization of TRAIL-R3, a Novel member of the Emerging Trail Receptor Family”, Journal of Experimental Medicine 186(7):1165-1170 (1997).
Delgi-Esposti et al., “The Novel Receptor TRAIL-R4 Induces NF-KB and Portects Against TRAIL-Mediated Apoptosis, yet Retains an Incomplete Death Domain”, Immunity 7:813-820 (1997).
Gazitt, Y., “TRAIL is a potent Inducer of Apoptosis in Myeloma Cells Derived from Multiple Myeloma Patients and is not Cytotoxic to Hematopoietic Stem Cells”, Leukemia 13:1817-1824 (1998).
Gliniak et al., “Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand's Antitumor Activity in Vivo is Enhanced by the Chemoptherapeutic Agent CPT-11”, Cancer Research 59:6153-6158 (1999).
Goodwin et al., “Molecular Cloning and Expression of the Type 1 and Type 2 Murine Receptors for Tumor Necrosis Factor”, Mol. Cell. Bio. 11:3020-3026 (1991).
Griffith et al., “Monocyte-mediated Tumoricidial Activity Via the Tumor Necrosis Factor—related Cytokine, TRAIL”, Journal of Experimental Medicine 189:1343-1353.
Gruss et al., “Tumor Necrosis Factor Ligand Superfamily: Involvement in the Pathology of Malignant Lymphomas”, Blood 85:3378-3404.
Hahne et al., “APRIL, A New Ligand of the Tumor Necrosis Factor Family, Stimulates Tumor Cell Growth”, Journal of Experimental Medicine 188(6):1185-1190 (1998).
Hale et al., “Demostration of In Vitro and In Vivo Efficacy of Two Biologically Active Human Soluble TNF Receptors Expressed inE. coli”, J. Cell Biochem (abstract only, supple. 15F, p. 424) pp. 113 (1991).
Hohman et al., “Two Different Cell Types Have Different Major Receptors for Human Necrosis Factor (TNFα)” Journal of Biological Chemistry 264:14927-14934 (1998).
Hymowitz et al., “A unique Zinc-Binding Site Revealed by the High-Resolution X-Ray Structure of Homotrimeric Apo2L/TRAIL” Biochemistry 39(4):633-640 (2000).
Hyymowitz et al., “Triggering Cell Death: The Crystal Structure of Apo2L/TRAIL in a Complex with Death Receptor 5”, Molecular Cell 4(4):563-571 (1999).
Itoh et al., “The Polypeptide Encoded by the cDNA for Human Cell Surface Antigen Fas can Mediate Apoptosis”, cell 66:233-243 (1991).
Jeremias et al., “TRAIL/Apo-2-Ligand-Induced Apoptosis in Human T Cells”, European Journal of Immunology 28:143-152 (1998).
Jo et al., “Apoptosis Induced in Normal Human Hepatocytes by Tumor Necrosis Factor-related Apoptosis-Inducing Ligand”, Nature Medicine 6(5):564-567 (2000).
Johnson et al., “Regulation of Apo-2 Ligand/TRAIL Expression in NK Cells-Involvement in NK Cell-Mediated Cytotoxicity”, Cytokine 11:664-672 (1999).
Johnson et al., “Expression and Structure of the Human NGF Receptor” Cell 47:545-554 (1986).
Katsikis et al., “Interleukin-1β Converting Enzyme-like Protease Involvement in FAS-Induced Peripheral Blood T Cell Apoptosis in HIV Infection. TNF-Related Apoptosis-Inducing Ligand can Mediate Activation-Induced T Cell Death in HIV Infection”, Journal of Experimental Medicine.
Keane, et al., “Chemotherapy Augments TRAIL-Induced Apoptosis in Breast Cell Lines”, Cancer Research 59:734-741(1999).
Kohno et al., “A Second Tumor Necrosis Factor Receptor Gene Product can Shed a Naturally Occuring Tumor Necrosis Factor Inhibitor”, Proc. Natl. Acad. Sci. USA 87:8331-8335 (1990).
Lawrence et al., “Differential Hepatocyte Toxicity of Recombinant Apo21/TRAIL Versions”, Nature Medicine 7(4):383-385 (2001).
Lweis et al., “Cloning and Expression of cNDAs for Two Distinct Murine Tumor Necrosis Factor Receptors Demostrates One Receptor is Species Specific”, PNAS USA 88:2830-2834 (1991).
Loetscher et al., “Molecular Cloning and Expression of the HUman 55 kd Tumor Necrosis Factor Receptor”, Cell 61:351-359 (1990).
MacFarlane et al., “Identification and Molecular Cloning of Two Novel Receptors for the Cytotoxic Ligand TRAIL” Journal of Biological Chemistry 272(41):25417-25420 (1997).
Mallet et al., “Characterization of the MRC OX40 Antigen of Activated CD4 Positive T Lymphocytes—A Molecule Related to Nerve Growth Factor Receptor”, EMBO Journal 9(4):1063-1068 (1990).
Mariani et al., “Interleukin 1β-Converting Enzyme Related Proteases/Caspases are Involved in Trail-Induced Apoptosis of Myeloma and Leukemia Cells”, Jour
Flores Heather
Lin Tanya P.
Matthews Timothy C.
Pai Roger
Shahrokh Zahra
Arnold & Porter LLP
Dreger, Esq. Ginger R.
Genentech Inc.
Marschang, Esq. Diane
Woodward Cherie M
LandOfFree
APO-2 ligand/trail formulations does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with APO-2 ligand/trail formulations, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and APO-2 ligand/trail formulations will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4156889